Gaucher Disease Type III - Pipeline Review, H2 2016 - Key Players are Actelion, Belrose Pharma, Erad Therapeutics, Genzyme Corp & Shire Plc - Research and Markets

DUBLIN--()--Research and Markets has announced the addition of the "Gaucher Disease Type III - Pipeline Review, H2 2016" report to their offering.

Gaucher disease type III also known as chronic neuronopathic Gaucher disease (subacute form of neuronopathic Gaucher disease). Symptoms include mental deterioration, ataxia, and myoclonic seizures. The cause of Gaucher disease III is the accumulation of a fatty material called glucocerebroside (also known as glucosylceramide) Treatment includes enzyme replacement therapy.

This report provides comprehensive information on the therapeutic development for Gaucher Disease Type III, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Gaucher Disease Type III and special features on late-stage and discontinued projects.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Key Topics Covered:

  1. Introduction
  2. Gaucher Disease Type III Overview
  3. Therapeutics Development
  4. Pipeline Products for Gaucher Disease Type III - Overview
  5. Pipeline Products for Gaucher Disease Type III - Comparative Analysis
  6. Gaucher Disease Type III - Therapeutics under Development by Companies
  7. Gaucher Disease Type III - Therapeutics under Investigation by Universities/Institutes
  8. Gaucher Disease Type III - Pipeline Products Glance
  9. Late Stage Products
  10. Clinical Stage Products
  11. Early Stage Products
  12. Gaucher Disease Type III - Products under Development by Companies
  13. Gaucher Disease Type III - Products under Investigation by Universities/Institutes
  14. Gaucher Disease Type III - Companies Involved in Therapeutics Development

Companies Mentioned

  • Actelion Ltd
  • Belrose Pharma Inc
  • Erad Therapeutics Inc
  • Genzyme Corp
  • Shire Plc

For more information about this report visit http://www.researchandmarkets.com/research/znrcbf/gaucher_disease

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T. Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Related Topics: Endocrine and Metabolic Disorders Drugs

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T. Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Related Topics: Endocrine and Metabolic Disorders Drugs